VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
VolitionRx Limited (AMEX: VNRX) has announced a conference call scheduled for March 16, 2023, at 08:30 a.m. Eastern Time, to discuss its full fiscal year 2022 financial and operating results, along with a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VolitionRx Limited (AMEX: VNRX) has announced a conference call scheduled for March 16, 2023, at 08:30 a.m. Eastern Time, to discuss its full fiscal year 2022 financial and operating results, along with a business update. CEO Cameron Reynolds, along with other executives, will address key events from 2022 and future milestones. A live audio webcast will be available on Volition's investor relations page, and a replay will be accessible until March 30, 2023. VolitionRx specializes in developing cost-effective blood tests for diagnosing and monitoring diseases using its proprietary Nu.Q® platform.
Positive
- Scheduled conference call to discuss full fiscal year 2022 results and business updates.
- Focus on innovative blood tests for early diagnosis and monitoring of diseases.
Negative
- None.
Details
News Market Reaction – VNRX
The recorded move for VNRX in the trading session of this news was -3.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to take place on
Event: VolitionRx Limited Full Year 2022 Earnings and Business Update Conference Call
Date:
Time:
Toll/International: 1-201-493-6779
Conference ID: 13736997
A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com. In addition, a telephone replay of the call will be available until
About Volition
Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in
Nu.Q® is a trademark of
Media Enquiries:
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-year-2022-earnings-conference-call-and-business-update-301768855.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.